Eden Biodesign and Stealthyx Therapeutics sign deal to develop enhanced treatment for rheumatoid arthritis
The product will incorporate Stealthyx Therapeutics' proprietary Prothyx technology that has been developed by Professor Yuti Chernajovsky at St. Bartholomews Hospital and The London, Queen Mary's School of Medicine and Dentistry, University of London. Prothyx harnesses the properties of a naturally occurring peptide to confer stability and disease targeting biological therapeutics resulting in improved efficacy and lower side effect profile.
This project has been funded by the National Biomanufacturing Centre (NBC) Access Fund administered by the Northwest Regional Development Agency (NWDA).
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.